Key result
Methyl palmitate delivers ~61% ACE inhibition and restores vascular architecture in hypertensive rats.
Why the study?
Synthetic ACE inhibitors are effective but have several side effects, and the ACE inhibitory and antihypertensive potential of methyl palmitate, a natural fatty acid methyl ester, has not been explored.
Methyl palmitate acts as a natural competitive ACE inhibitor that mitigates hypertension-induced vascular damage and oxidative stress in a rat model, suggesting therapeutic potential for vascular protection rather than rapid blood pressure reduction.
Answers are grounded in this paper and cite their sources.
Should not alter clinical practice; leaves open translational studies of methyl palmitate for vascular protection in hypertension.
Introduction: Angiotensin converting enzyme (ACE) regulates blood pressure via the renin-angiotensin and bradykinin systems. Though synthetic ACE inhibitors are more effective, they pose several side effects. Methyl palmitate (MP), a natural fatty acid methyl ester with cytoprotective, antioxidant, anti-inflammatory, and vasodilatory properties, is not explored for its ACE inhibitory or antihypertensive potential. This study aimed to investigate the in vitro ACE inhibition of MP and its effect on L-NG-Nitro Arginine Methyl Ester (L-NAME)-induced hypertensive male Wistar rats. METHODS: An in vitro ACE inhibition assay was conducted to compare the inhibition potency of MP with that of lisinopril. Male Wistar rats (n = 35, 7 per group) were grouped into control, disease control, and treatment groups receiving 100, 150, or 200 mg/kg/day of MP for 21 days each. Blood pressure, serum ACE activity, malondialdehyde (MDA), and nitric oxide (NO) levels in kidney tissue homogenate, and thoracic aorta histopathology were assessed. RESULTS: MP inhibited ACE by 61.05% at 5 µm, exceeding lisinopril's 41.67%. High-dose MP significantly reduced serum ACE and MDA levels, while increasing NO (p < 0.001). Histopathology revealed near-normal vasculature, although changes in blood pressure were not statistically significant (p > 0.05). CONCLUSION: MP demonstrates strong natural ACE inhibition, antioxidant, and vascular protective effects, supporting further research for therapeutic optimization. .
No takes yet. Share an insight, caveat, or question.
Rao et al. (2026) studied Hypertension (L-NAME-induced model) (n=35). Methyl Palmitate vs. Disease control (L-NAME 40 mg/kg/day without intervention) and Normal control was evaluated on In vitro ACE inhibition at 5 µm. Methyl palmitate demonstrated potent in vitro ACE inhibition and reduced in vivo serum ACE and oxidative stress markers, restoring vascular architecture in hypertensive rats, despite non-significant blood pressure changes.
Synapse has enriched 10 related papers. Consider them for comparative context: